Iblias

RSS
Withdrawn

This medicine's authorisation has been withdrawn

octocog alfa
Medicine Human Withdrawn
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 3 September 2019, the European Commission withdrew the marketing authorisation for Iblias (octocog alfa) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Bayer AG, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Iblias was granted marketing authorisation in the EU on 18 February 2016 for treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). The marketing authorisation was initially valid for a 5-year period. The product had not been marketed in the EU since 2018. 

The European Public Assessment Report (EPAR) for Iblias is updated to indicate that the marketing authorisation is no longer valid.

Iblias : EPAR - Summary for the public

Reference Number: EMEA/H/C/004147

English (EN) (664.7 KB - PDF)

First published: Last updated:
View

български (BG) (728.12 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

español (ES) (1.17 MB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

čeština (CS) (708.58 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

dansk (DA) (633.88 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

Deutsch (DE) (635.46 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

eesti keel (ET) (631.72 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

ελληνικά (EL) (731.97 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

français (FR) (635.97 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

hrvatski (HR) (656.29 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

italiano (IT) (633.83 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

latviešu valoda (LV) (707.69 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

lietuvių kalba (LT) (659.06 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

magyar (HU) (701.65 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

Malti (MT) (709.33 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

Nederlands (NL) (634.13 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

polski (PL) (707.63 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

português (PT) (634.9 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

română (RO) (655.77 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

slovenčina (SK) (706.67 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

slovenščina (SL) (701.11 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

Suomi (FI) (633.26 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

svenska (SV) (663.78 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

Iblias : EPAR - Risk-management-plan summary

Reference Number: EMA/1562/2016

English (EN) (615.14 KB - PDF)

First published: Last updated:
View

Product information

Iblias : EPAR - Product Information

English (EN) (833.63 KB - PDF)

First published: Last updated:
View

български (BG) (2.24 MB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

español (ES) (809.65 KB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

čeština (CS) (1.5 MB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

dansk (DA) (1.16 MB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

Deutsch (DE) (813.96 KB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

eesti keel (ET) (802.89 KB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

ελληνικά (EL) (1.97 MB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

français (FR) (1.23 MB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

hrvatski (HR) (1.21 MB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

íslenska (IS) (973.6 KB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

italiano (IT) (810.4 KB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

latviešu valoda (LV) (1.57 MB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

lietuvių kalba (LT) (910.21 KB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

magyar (HU) (1.49 MB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

Malti (MT) (1.89 MB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

Nederlands (NL) (835.73 KB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

norsk (NO) (760.73 KB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

polski (PL) (1.55 MB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

português (PT) (825.77 KB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

română (RO) (1.25 MB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

slovenčina (SK) (1.61 MB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

slovenščina (SL) (1.51 MB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

Suomi (FI) (815.83 KB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View

svenska (SV) (825.87 KB - PDF)

First published: 09/03/2016 Last updated: 27/04/2018
View
Latest procedure affecting product information:A31/0002
10/11/2017
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Iblias : EPAR - All Authorised presentations

English (EN) (575.64 KB - PDF)

First published: Last updated:
View

български (BG) (596.48 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

español (ES) (575.54 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

čeština (CS) (601.52 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

dansk (DA) (574.47 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

Deutsch (DE) (574.02 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

eesti keel (ET) (574.22 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

ελληνικά (EL) (617.28 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

français (FR) (574.01 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

hrvatski (HR) (585.23 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

íslenska (IS) (574.53 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

italiano (IT) (573.99 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

latviešu valoda (LV) (604.11 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

lietuvių kalba (LT) (585.62 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

magyar (HU) (600.67 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

Malti (MT) (602.23 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

Nederlands (NL) (575.64 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

norsk (NO) (575.56 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

polski (PL) (602.55 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

português (PT) (575.48 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

română (RO) (587.68 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

slovenčina (SK) (600.53 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

slovenščina (SL) (589.67 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

Suomi (FI) (574.13 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

svenska (SV) (574.27 KB - PDF)

First published: 09/03/2016 Last updated: 09/03/2016
View

Product details

Name of medicine
Iblias
Active substance
Octocog alfa
International non-proprietary name (INN) or common name
octocog alfa
Therapeutic area (MeSH)
Hemophilia A
Anatomical therapeutic chemical (ATC) code
B02BD02

Pharmacotherapeutic group

Antihemorrhagics

Therapeutic indication

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
Iblias can be used for all age groups.

Authorisation details

EMA product number
EMEA/H/C/004147
Marketing authorisation holder
Bayer AG

51368 Leverkusen 
Germany

Marketing authorisation issued
18/02/2016
Revision
4

Assessment history

Iblias : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (643.27 KB - PDF)

First published: Last updated:
View

Iblias-H-C-4147-A31-0002 : EPAR - Assessment Report - Article 31

Adopted Reference Number: EMA/763977/2017

English (EN) (905.9 KB - PDF)

First published: Last updated:
View

Iblias : EPAR - Public assessment report

Adopted Reference Number: EMA/CHMP/71742/2016

English (EN) (2.47 MB - PDF)

First published: Last updated:
View

CHMP summary of opinion for Iblias

Adopted Reference Number: EMA/CHMP/774757/2015

English (EN) (623.74 KB - PDF)

First published: Last updated:
View
This page was last updated on

Share this page

Back to top